Emergent BioSolutions (EBS) Misses Q4 EPS by 81c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.80 -3.13%
EPS Growth %: -138.7%
Financial Fact:
Research and development: 27.19M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -138.7%
Financial Fact:
Research and development: 27.19M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of ($0.43), $0.81 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $148.7 million versus the consensus estimate of $237 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- Nscale files for IPO, seeks NYSE listing under ticker NSCL
- Axion Minerals plans flow-through private placement of up to $440K
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
